( BW)(GENDUX-MOLECULAR)(INGN) Gendux Announces Acceptance of Its
ADVEXIN Marketing Authorization Application for Review by the EMEA;
Gene Therapy Targeting Inherited Cancer is World's First

    Business Editors/Health/Medical Writers

    DUBLIN--(BUSINESS WIRE)--Nov. 27, 2007--Gendux Molecular Limited
("Gendux") announced today that its Marketing Authorization
Application ("MAA") for ADVEXIN(R) ("contusugene ladenovec") has been
accepted for technical review by the European medicines regulatory
authority (the "EMEA") for the treatment of an inherited cancer,
Li-Fraumeni Syndrome ("LFS"). Gendux announced the submission of its
MAA for ADVEXIN with the EMEA on 13th November 2007. ADVEXIN is the
first treatment specific for an inherited cancer syndrome. ADVEXIN
acts by reversing one of the most common cancer genetic defects,
abnormal p53 tumor suppressor levels that are inherited in Li-Fraumeni
patients and which are found in the majority of non-inherited cancers.
ADVEXIN is also being developed for head and neck cancer and filings
for this indication are anticipated before the end of 2007 both in
Europe and the US.

    The acceptance of the MAA for ADVEXIN will initiate the regulatory
review of the Application's preclinical, manufacturing and clinical
data by the EMEA. Gendux is utilizing the Exceptional Circumstances
Approval rules available in Europe to expedite review of potential
breakthrough therapies. The review will be based on clinical efficacy
and safety results from the use of ADVEXIN in LFS and in a wide
variety of non-inherited cancers with abnormal p53 tumor suppression,
the target of ADVEXIN treatment. Abnormal p53 is inherited in LFS and
is also the most commonly identified defective gene in all solid
cancers whether inherited or acquired. An important aspect of ADVEXIN
therapy is that patients' tumors can be checked to determine if they
have the p53 abnormality targeted by ADVEXIN using widely available
diagnostic tests.

    Dr. Max Talbott, senior vice president of Worldwide Regulatory
Affairs, said, "The acceptance of our ADVEXIN application is a
historic moment in the development of gene therapy. If approved,
ADVEXIN will be the world's first specific treatment for an inherited
cancer syndrome and could represent a totally novel, personalized
approach for a broad range of cancers. The EMEA's response to our
filing reflects both the regulatory quality of our Application and the
EMEA's readiness to begin the technical review. We look forward to our
interactions with the EMEA and the opportunity of bringing this
breakthrough treatment to the market as quickly as possible for the
treatment of this devastating disorder."

    About ADVEXIN

    ADVEXIN p53 therapy is a targeted gene therapy with broad
applicability in a wide range of tumor types and clinical settings
because it targets one of the most fundamental and common molecular
defects, abnormal p53 tumor suppressor function, associated with
cancer initiation, progression and treatment resistance. ADVEXIN has
demonstrated tumor growth control in recurrent head and neck cancer,
lung cancer, breast cancer, esophageal, prostate and other cancer
indications. ADVEXIN has demonstrated clinical activity in a number of
solid tumor types in multiple phase 1, 2 and 3 clinical trials
conducted worldwide.

    About Li-Fraumeni Syndrome

    LFS is a cancer syndrome characterized by the inheritance of an
abnormal p53 tumor suppressor. Normal p53, known as the Guardian of
the Genome, suppresses cancer and tumor formation. Without p53 tumor
suppression, cancer patients can lose the ability to naturally combat
cancer. Without a normally functioning p53 defence, LFS cancer
patients often develop spontaneous and widespread tumors at an early
age. Frequently, multiple members of the same family suffer from this
genetic disorder and currently there are no approved therapies to
specifically treat LFS.

    About Gendux Molecular Limited

    Gendux Molecular Limited is a non-resident Irish company based in
Dublin, Ireland. The Company is focused on the commercialization of
targeted molecular therapies to be applied with molecular diagnostic
tools to introduce personalized medical products in European and other
markets. Gendux is a subsidiary of Introgen Therapeutics, Inc. For
more information on Gendux, or for a menu of archived press releases,
please visit Gendux's Website at: www.gendux.ie.

    About Introgen Therapeutics, Inc.

    Introgen (NASDAQ:INGN) is a biopharmaceutical company focused on
the development, manufacturing and commercialization of targeted tumor
suppressors, a new class of therapies for the treatment of cancer.
Introgen's technology delivers targeted molecular therapies that
increase production of normal cancer-fighting proteins and cytokines.
Introgen is developing a proprietary pipeline of product candidates
utilizing molecular biomarkers to identify patients most likely to
benefit from its therapies which target central cancer-causing
mechanisms. For more information on Introgen Therapeutics, or for a
menu of archived press releases, please visit Introgen's Website at:
www.introgen.com.

    Forward-Looking Statements

    Statements in this release that are not strictly historical may be
"forward-looking" statements, including those relating to Introgen's
future success with its ADVEXIN clinical development program for
treatment of LFS cancers, the approval of ADVEXIN for LFS in European
markets, and the acceptance of Gendux Molecular Limited's Marketing
Authorization Application. The actual results may differ from those
described in this release due to risks and uncertainties that exist in
Introgen's operations and business environment, including Introgen's
stage of product development and the limited experience in the
development of gene-based drugs in general, dependence upon
proprietary technology and the current competitive environment,
history of operating losses and accumulated deficits, reliance on
collaborative relationships, and uncertainties related to clinical
trials, the safety and efficacy of Introgen's product candidates, the
ability to obtain the appropriate regulatory approvals, Introgen's
patent protection and market acceptance, as well as other risks
detailed from time to time in Introgen's filings with the Securities
and Exchange Commission including its filings on Form 10-K and Form
10-Q. Introgen undertakes no obligation to publicly release the
results of any revisions to any forward-looking statements that
reflect events or circumstances arising after the date hereof.

    --30--BD/sa*

    CONTACT: Gendux Molecular Limited
             C. Channing Burke, +353-1-408-6949
             or +1-512-708-9310 Ext. 322
             c.burke@gendux.com
             or
             Citigate Dewe Rogerson
             David Dible, +44(0)20 7638 9571
             david.dible@citigatedr.co.uk
             or
             Yvonne Alexander, +44(0)20 7638 9571



Disclaimer: Deze bekendmaking is officieel geldend in de originele 
brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten 
worden vergeleken met de tekst in de brontaal welke als enige, 
juridische geldigheid beoogt.